Evidence map›Paper›PMID 28727774›Full record

ArticlePloS one2017

Inhibitors of Mycobacterium marinum virulence identified in a Dictyostelium discoideum host model.

Hajer Ouertatani-Sakouhi, Sébastien Kicka, Gianpaolo Chiriano, Christopher F Harrison, Hubert Hilbi, Leonardo Scapozza, Thierry Soldati, Pierre Cosson

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Identification of Anti-Frontiers in microbiology · 2020
    Article
  8. Editorial: Amoebae as Host Models to Study the Interaction With Pathogens.Frontiers in cellular and infection microbiology · 2019
    Article
  9. Article
  10. Inorganic Polyphosphate Is Essential forFrontiers in cellular and infection microbiology · 2018
    Article
  11. Article
  12. Eat Prey, Live:Frontiers in immunology · 2017
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hajer Ouertatani-SakouhiFaculty of Medicine, Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.
Sébastien KickaDepartment of Biochemistry, University of Geneva, Geneva, Switzerland.
Gianpaolo ChirianoPharmaceutical biochemistry, School of pharmaceutical sciences, University of Geneva, University of Lausanne, 30 Quai Ernst Ansermet, Geneva, Switzerland.
Christopher F HarrisonMax von Pettenkofer Institute, Department of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.
Hubert HilbiMax von Pettenkofer Institute, Department of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.
Leonardo ScapozzaPharmaceutical biochemistry, School of pharmaceutical sciences, University of Geneva, University of Lausanne, 30 Quai Ernst Ansermet, Geneva, Switzerland.
Thierry SoldatiDepartment of Biochemistry, University of Geneva, Geneva, Switzerland.
Pierre CossonFaculty of Medicine, Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-4881-0358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis remains one of the major threats to public health worldwide. Given the prevalence of multi drug resistance (MDR) in Mycobacterium tuberculosis strains, there is a strong need to develop new anti-mycobacterial drugs with modes of action distinct from classical antibiotics. Inhibitors of mycobacterial virulence might target new molecular processes and may represent a potential new therapeutic alternative. In this study, we used a Dictyostelium discoideum host model to assess virulence of Mycobacterium marinum and to identify compounds inhibiting mycobacterial virulence. Among 9995 chemical compounds, we selected 12 inhibitors of mycobacterial virulence that do not inhibit mycobacterial growth in synthetic medium. Further analyses revealed that 8 of them perturbed functions requiring an intact mycobacterial cell wall such as sliding motility, bacterial aggregation or cell wall permeability. Chemical analogs of two compounds were analyzed. Chemical modifications altered concomitantly their effect on sliding motility and on mycobacterial virulence, suggesting that the alteration of the mycobacterial cell wall caused the loss of virulence. We characterized further one of the selected compounds and found that it inhibited the ability of mycobacteria to replicate in infected cells. Together these results identify new antimycobacterial compounds that represent new tools to unravel the molecular mechanisms controlling mycobacterial pathogenicity. The isolation of compounds with anti-virulence activity is the first step towards developing new antibacterial treatments.

Indexed as

DictyosteliumDrug Evaluation, PreclinicalMycobacterium marinumSmall Molecule LibrariesVirulenceSmall Molecule Libraries

Identifiers

PMID28727774
PMCPMC5519057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.